Abstract 96P
Background
Brain metastases (BM) due to colorectal cancer (CRC) are an infrequent event. Previous research suggests that patients with pulmonary metastases, rectal primaries and KRAS mutations are at an increased risk of BM. Despite multidisciplinary treatment, survival following BM remains poor. We aimed to analyse the incidence, genomic profiling, treatment administered and survival in patients with BM from CRC within our cancer service.
Methods
A retrospective analysis of 1346 CRC patients at two comprehensive cancer centres in Western Sydney identified 52 patients with BM. Data was subsequently collected on patient demographics, tumour and treatment characteristics. KRAS and BRAF mutation status from primary colorectal tumour specimens and surgical resection of BM was assessed. Survival data was analysed by the Kaplan-Meier method.
Results
The incidence of BM in our cohort was 3.9%. The mean age of patients was 66 (35-82) with 48% female and 52% male in the BM group compared to 36% female and 64% male in the non-BM group. 33% of patients were wildtype (WT), 62% had a RAS mutation and 5% were BRAF mutant. The median time between diagnosis of primary CRC and development of BM did not differ between RAS, RAF and WT (37, 50 and 43 months). 70% of WT patients presented with one BM compared to 45% of KRAS mutated patients although this was not statistically significant (p = 0.13). 38% of patients had surgery while 81% had radiotherapy (56% WBRT, 44% SRS) to treat their BM. The median PFS across all groups was 3.2 months and median OS was 3.9 months. Median PFS was significantly longer in patients who received surgery, chemotherapy and radiotherapy following their diagnosis of BM (12.3 months) versus surgery alone (1 month) or surgery and radiotherapy (4.4 months) (p = 0.022). Mutational status or number of BM did not impact on PFS or OS. Patients with synchronous liver metastases had a significantly shorter median OS of 3 months versus 13 months in those without liver metastases (p = 0.008).
Conclusions
Brain metastases remains an infrequent event in patients with metastatic colorectal cancer. KRAS and BRAF mutations do not appear to have any effect on prognosis or response to treatment in CRC patients with BM. Survival of CRC patients following BM is poor and novel approaches are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Western Sydney Local Health District.
Disclosure
K.Y.M. Wong: Advisory / Consultancy: Baxalta; Speaker Bureau / Expert testimony: Sirtex; Travel / ccommodation / Expenses: MSD Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract